Ixekizumab helps patients achieve recommended treatment goals

  • J Am Acad Dermatol

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Ixekizumab is associated with improvements in National Psoriasis Foundation (NPF)-defined treatment targets for patients with plaque psoriasis.

Why this matters

  • The ability of existing therapies to meet treatment targets has not been well studied.

Key results

  • Ixekizumab every 2 weeks (Q2W) was associated with an acceptable response (AR) rate of 73.9% and a target response (TR) rate of 51.8% in pooled analysis of the UNCOVER-1, UNCOVER-2, and UNCOVER-3 trials.
    • Etanercept was associated with a 35.7% AR rate and a 14.9% TR rate (P<.001 vs ixekizumab for both>
  • Ixekizumab Q2W was associated with an AR rate of 68.4% and a TR rate of 50.7% in the IXORA-A trial.
    • Ustekinumab was associated with an AR rate of 38.6% and a TR rate of 24.1% (P<.0001 vs ixekizumab for both>

Study design

  • 2701 patients with plaque psoriasis from the UNCOVER studies and 302 from the IXORA-S study were included in post-hoc pooled analysis.
  • The NPF defines AR as body surface area affected (BSA) ≤3% or BSA improvement ≥75% at 12 weeks of treatment and TR as BSA ≤1% at 12 weeks and every 6 months thereafter.
  • Funding: Eli Lilly and Company.

Limitations

  • Post-hoc analyses.
  • Trial data may not reflect real-world practice.